EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
31/07/2026
Voltar para busca
Dado oficial do USPTO
MONJUVI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
04/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
06/11/2019
Data de registro
13/10/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/07/2026
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
3
Tipo de titular
03
Localização do titular
Wilmington, DE, US
Examinador
POWERS, ALEXANDER L
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the term "MONJUVI" having a spherical shape appearing above the "i".
Titulares e representantes
Titulares
INCYTE HOLDINGS CORPORATION
MorphoSys AG
Representantes
Keith Toms, Esq. McCarter & English, LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorderscancerinflammatory diseasesrestenosis; vaccine preparations; vaccines; biological preparations in the nature of antibodies for use in the treatment of metabolic disorderscancerinflammatory diseasesrestenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorderscancerinflammatory diseasesrestenosis; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for use in the treatment and prevention of metabolic disorderscancerinflammatory diseasesrestenosis; diagnostic preparations for medical or veterinary purposes; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorderscancerinflammatory diseasesrestenosis; sanitary preparations for medical use; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for use in the treatment of metabolic disorderscancerinflammatory diseasesrestenosis; none of the foregoing goods for use in connection with the treatment or prevention of ear disorders
Classe 42
Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design servicesscientific researchanalysistesting services in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimersepsisrestenosis; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
31/07/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/07/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/07/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
31/07/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
31/07/2026
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
16/07/2026
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
16/07/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
13/07/2026
E815
TEAS SECTION 8 & 15 RECEIVED
10/04/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
13/10/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/06/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/06/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/06/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/06/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/06/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
01/05/2024
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
24/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
13/10/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/07/2020
PUBO
PUBLISHED FOR OPPOSITION
28/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/06/2020
ALIE
ASSIGNED TO LIE
18/06/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/06/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
18/12/2019
GNRT
NON-FINAL ACTION E-MAILED
18/12/2019
CNRT
NON-FINAL ACTION WRITTEN
18/12/2019
DOCK
ASSIGNED TO EXAMINER
15/12/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
15/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/11/2019
NWAP
NEW APPLICATION ENTERED
09/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MONJUVI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.